Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
Conditions:   Hematopoietic and Lymphoid Cell Neoplasm;   Malignant Solid Neoplasm
Interventions:   Radiation: Copper Cu 64-DOTA-pembrolizumab;   Biological: Pembrolizumab;   Procedure: Positron Emission Tomography
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 29, 2020 / by / in
Comments